Caplacizumab (Cablivi)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 03:09, 2 December 2016 by Dryang (talk | contribs) (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm")
Jump to navigation Jump to search

Mechanism of action

A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).

Preliminary data

Thrombotic thrombocytopenic purpura

  1. Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Caplacizumab_(Cablivi)&oldid=12610"